<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04793932</url>
  </required_header>
  <id_info>
    <org_study_id>PACT21</org_study_id>
    <nct_id>NCT04793932</nct_id>
  </id_info>
  <brief_title>Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL)</brief_title>
  <acronym>CASSANDRA</acronym>
  <official_title>A Randomized Phase II Trial of Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG Regimen for Stage I-III Pancreatic Ductal Adenocarcinoma (PDAC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Associazione Italiana per lo Studio del Pancreas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>High Research srl</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Associazione Italiana per lo Studio del Pancreas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of this study is to compare the efficacy of short-course versus long-course&#xD;
      pre-operative chemotherapy with PAXG or mFOLFIRINOX in patients who receive a diagnosis of&#xD;
      pancreatic ductal adenocarcinoma (PDAC) resectable or borderline resectable.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic cancer is the seventh cause of death in cancer patients and more than 94% of&#xD;
      affected patients die of cancer disease. In the majority of cases, the diagnosis is done at&#xD;
      an advanced stage and only 10-20% of patients can be treated with a surgical resection. For&#xD;
      this neoplasia, a radical resection may be an effective treatment. Nevertheless, results&#xD;
      obtained with surgery alone are rather inadequate, showing a median survival of 12-14 months&#xD;
      and 2-year survival of almost 20%: it seems evident the necessity to use complementary&#xD;
      treatments in order to improve survival rate in this group of patients.&#xD;
&#xD;
      Pancreatic cancer can relapse locally, at the level of tumoral bed, of the regional lymph&#xD;
      nodes, on the immediately adjacent peritoneal surface or on contiguous organs. Also, distant&#xD;
      metastases are quite frequent, mainly to the liver, at the entire peritoneal surface and,&#xD;
      rarely, to the extra-abdominal organs. The rapid appearance of these metastases after&#xD;
      surgical resection strongly suggests the presence of subclinical metastatic diffusion at an&#xD;
      early phase of the disease.&#xD;
&#xD;
      Currently, combination chemotherapy based on the mFOLFIRINOX regimen is considered the&#xD;
      therapeutic standard in the adjuvant setting, in young and fit patients. Unfortunately,&#xD;
      mFOLFIRINOX is burdened with strong haematological and extra-haematologic toxicity and just&#xD;
      2/3 of patients are able to complete the treatment. Recently, PAXG regimen [(Cisplatin (P),&#xD;
      Abraxane (A), Capecitabine (X), Gemcitabine (G)] when compared to AG in randomized studies,&#xD;
      showed an improvement in terms of progression-free survival (PFS) and overall survival in&#xD;
      borderline resectable, locally advanced and metastatic patients. To date, several ongoing&#xD;
      randomized trials are investigating the efficacy of perioperative or neoadjuvant strategies&#xD;
      in early stage PDAC. Only few studies are available regarding neoadjuvant treatment: some are&#xD;
      outdated, numerically inconsistent, retrospective, or not randomized. In this scenario, it&#xD;
      aims to better investigate pre-operative therapeutic strategy.&#xD;
&#xD;
      For this purpose, two randomizations are planned.&#xD;
&#xD;
        1. FIRST RANDOMIZATION. Eligible patients will be randomized (1:1), stratifying by basal&#xD;
           CA19.9 level (&lt;5 ULN vs ≥ 5ULN) and centre to receive:&#xD;
&#xD;
           PAXG or mFOLFIRINOX for 4 months&#xD;
&#xD;
        2. SECOND RANDOMIZATION. Patients without progression or limiting toxicity after 4 months&#xD;
           of the assigned chemotherapy in the study, will be randomized (1:1), stratifying by&#xD;
           treatment assigned by the first randomization, to receive 2 further months of the same&#xD;
           chemotherapy either BEFORE or AFTER surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2020</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>2 by 2</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy of PAXG versus mFOLFIRINOX in terms of EFS</measure>
    <time_frame>12 weeks</time_frame>
    <description>to compare in terms of event free survival (EFS) the efficacy of PAXG to that of mFOLFIRINOX. EFS is defined as the time from randomization to: RECIST 1.1 progression [At least a 20 percent increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20 percent, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression]; CA19.9 failure (defined as 2 consecutive increases of serum level ≥20 percent, separated by at least 4 weeks); recurrence; preoperative or intraoperative unresectability; intraoperative evidence of metastases; death for any cause; whichever occurs first. R1 resections will NOT be considered as events whereas R2 resections will be.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The efficacy of short-course versus long-course therapy in terms of EFS</measure>
    <time_frame>12 weeks</time_frame>
    <description>to compare in terms of event free survival (EFS) the efficacy of 4 months pre-operative and 2 months postoperative chemotherapy to that of 6 months of pre-operative chemotherapy . EFS is defined as the time from randomization to: RECIST 1.1 progression [At least a 20 percent increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20 percent, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression]; CA19.9 failure (defined as 2 consecutive increases of serum level ≥20 percent, separated by at least 4 weeks); recurrence; preoperative or intraoperative unresectability; intraoperative evidence of metastases; death for any cause; whichever occurs first. R1 resections will NOT be considered as events whereas R2 resections will be.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>36 months</time_frame>
    <description>the time between the date of the patient's enrollment and the death of the patient for any cause or the last time the patient was seen alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RECIST 1.1 radiological response</measure>
    <time_frame>4-6 months</time_frame>
    <description>Radiological response evaluation during the treatment by using RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ca19.9 response rate</measure>
    <time_frame>4-6 months</time_frame>
    <description>Biochemical response evaluation during the treatment by using this specific marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery outcome</measure>
    <time_frame>4-6 months after chemotherapy</time_frame>
    <description>The evaluation of resectability rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery outcome</measure>
    <time_frame>4-6 months after chemotherapy</time_frame>
    <description>The evaluation of surgical mortality and morbidity rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery outcome</measure>
    <time_frame>4-6 months after chemotherapy</time_frame>
    <description>The evaluation of intra- and post-operative metastasis rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery outcome</measure>
    <time_frame>4-6 months after chemotherapy</time_frame>
    <description>The evaluation of N0 and R0 resections rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment Adverse Events</measure>
    <time_frame>4-6 months</time_frame>
    <description>The evaluation of drugs safety and tolerability by SAE report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>4-6 months</time_frame>
    <description>Impact of treatment on quality of life assessed by the latest version of the European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>4-6 months</time_frame>
    <description>Impact of treatment on quality of life assessed by the European Organization for Research and Treatment of Cancer Quality of Life scale for pancreatic cancer (EORTC QLQ - PAN26)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">261</enrollment>
  <condition>Pancreas Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>PAXG Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cisplatin 30 mg/m2 every 2 weeks, nab-paclitaxel 150 mg/m2 every 2 weeks, gemcitabine 800 mg/m2 every 2 weeks, capecitabine 1250 mg/m2/day (for 28 consecutive days) in 28-day cycles administered for 4 cycles (4 months).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mFOLFIRINOX Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>irinotecan 150 mg/m2 day 1, oxaliplatin 85 mg/m2 day 1, folinic acid at a fixed dose of 400 mg/m2, fluorouracil continuous IV infusion 2.4 g/m2 over 46 hours in 14-day cycles administered for 8 cycles (4 months).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>short-course chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allocated by second randomization after 4 months of chemotherapy to receive immediate surgery followed by 2 further months of the same chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>long-course chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allocated by second randomization after 4 months of chemotherapy to receive 2 further months of the same chemotherapy followed by surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAXG</intervention_name>
    <description>Nab-paclitaxel, cisplatin and gemcitabine drugs will be administered on day 1 and 15 every 28 days. Capecitabine tablets will be taken orally on days 1 to 28, every 28 days</description>
    <arm_group_label>PAXG Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFIRINOX</intervention_name>
    <description>Oxaliplatin, folinic acid, irinotecan and 5-Fluoruracil will be administered on day 1 and 15 every 28 days</description>
    <arm_group_label>mFOLFIRINOX Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>short-course chemotherapy</intervention_name>
    <description>other two months of chemotherapy after surgery</description>
    <arm_group_label>short-course chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>long-course chemotherapy</intervention_name>
    <description>other two months of chemotherapy before surgery</description>
    <arm_group_label>long-course chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Cyto/histological diagnosis of pancreatic ductal adenocarcinoma*;&#xD;
&#xD;
          2. Clinical stage I-III disease according to TNM 8th Ed. 2017 [appendix 1];&#xD;
&#xD;
          3. Resectable or borderline resectable disease, as anatomically defined according to NCCN&#xD;
             Guidelines Version 1.2020 - Pancreatic Adenocarcinoma [appendix 2] and biologically&#xD;
             defined according to the International consensus on definition and criteria of&#xD;
             borderline resectable pancreatic ductal adenocarcinoma 2017 (CA 19.9 &gt; 500 IU/ml)&#xD;
             (Isaji et al., 2018);&#xD;
&#xD;
          4. Karnofsky Performance Status &gt; 60% [appendix 3];&#xD;
&#xD;
          5. Age 18 and ≤ 75 years;&#xD;
&#xD;
          6. Adequate bone marrow function (GB ≥ 3500/mm3, neutrophils ≥1500/mm3, platelets ≥&#xD;
             100000/mm3, Hb ≥10 g/dl);&#xD;
&#xD;
          7. Adequate kidney function (serum creatinine &lt; 1.5 mg/dL);&#xD;
&#xD;
          8. Adequate liver function (ALT and AST &lt; 3 ULN and Serum total bilirubin ≤ 1.5 ULN);&#xD;
&#xD;
          9. No prior treatment (chemotherapy, radiotherapy and/or surgery) for pancreatic cancer;&#xD;
&#xD;
         10. Women must not be on pregnancy or lactation;&#xD;
&#xD;
         11. Patient of child-bearing potential must agree to use two medically acceptable methods&#xD;
             of contraception (one for the patient and one for the partner) during the study and&#xD;
             for a minimum of the following 6 months; this applies to patients of both sexes.&#xD;
             [appendix 4];&#xD;
&#xD;
         12. Patient information and signed written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other types of non-ductal tumor of the pancreas, including endocrine tumors or acinar&#xD;
             cell adenocarcinoma, cystadenocarcinoma and other periampullary malignancies.&#xD;
&#xD;
          2. Prior or concurrent malignancies at other sites with the exception of surgically cured&#xD;
             carcinoma in-situ of the cervix and basal or squamous cell carcinoma of the skin and&#xD;
             of other neoplasms without evidence of disease at least from 5 years;&#xD;
&#xD;
          3. Symptomatic duodenal stenosis;&#xD;
&#xD;
          4. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic&#xD;
             therapy, defined as ongoing signs/symptoms related to the infection without&#xD;
             improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment&#xD;
&#xD;
          5. Known infection with hepatitis B or C, or history of human immunodeficiency virus&#xD;
             (HIV) infection, or subject receiving immunosuppressive or myelosuppressive&#xD;
             medications that would in the opinion of the investigator, increase the risk of&#xD;
             serious neutropenic complications&#xD;
&#xD;
          6. Clinical stage IV (including ascites or malignant pleural effusion) disease according&#xD;
             to TNM 8th Ed. 2017 [appendix 1];&#xD;
&#xD;
          7. Locally advanced disease according to NCCN Guidelines Version 1.2020 - Pancreatic&#xD;
             Adenocarcinoma [appendix 2];&#xD;
&#xD;
          8. Serious medical risk factors involving any of the major organ systems, or serious&#xD;
             psychiatric disorders, which could compromise the subject's safety or the study data&#xD;
             integrity. These include, but are not limited to:&#xD;
&#xD;
               1. History of connective tissue disorders (eg, lupus, scleroderma, arteritis nodosa)&#xD;
&#xD;
               2. History of interstitial lung disease, slowly progressive dyspnea and unproductive&#xD;
                  cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary&#xD;
                  hypersensitivity pneumonitis or multiple allergies&#xD;
&#xD;
               3. History of the following within 6 months prior to Cycle 1 Day 1: a myocardial&#xD;
                  infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass&#xD;
                  graft, New York Heart Association (NYHA) Class III-IV heart failure, uncontrolled&#xD;
                  hypertension, clinically significant cardiac dysrhythmia or ECG abnormality,&#xD;
                  cerebrovascular accident, transient ischemic attack, or seizure disorder&#xD;
&#xD;
          9. Any significant medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would prevent the subject from participating in the study&#xD;
&#xD;
         10. Any condition including the presence of laboratory abnormalities, which places the&#xD;
             subject at unacceptable risk if he/she were to participate in the study&#xD;
&#xD;
         11. Any condition that confounds the ability to interpret data from the study&#xD;
&#xD;
         12. Any familiar, sociologic or geographic conditions that can potentially interfere with&#xD;
             the adhesion to the protocol or to the follow-up;&#xD;
&#xD;
         13. Pre-existing neuropathy, Gilbert's disease or genotype UGT1A1 * 28 / * 28.&#xD;
&#xD;
         14. mutation in DPYD&#xD;
&#xD;
         15. Inflammatory disease of the colon or rectum, or occlusion or sub-occlusion of the&#xD;
             intestine.&#xD;
&#xD;
         16. Concurrent treatment with other experimental drugs;&#xD;
&#xD;
         17. Fructose intolerance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Reni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS San Raffaele</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michele Reni, MD</last_name>
    <phone>+390226437644</phone>
    <email>reni.michele@hsr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Maddalena Valente, PhD</last_name>
    <phone>+390226437623</phone>
    <email>valente.mariamaddalena@hsr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oncologia Medica e Prevenzione Oncologica Centro di riferimento oncologico (CRO), IRCCS</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angela Buonadonna, MD</last_name>
      <phone>+390434659190</phone>
      <email>abuonadonna@cro.it</email>
    </contact>
    <contact_backup>
      <last_name>Claudio Bellulo, MD</last_name>
      <phone>+390434659047</phone>
      <email>cbellulo@cro.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica Az. Ospedaliera Istituto Tumori &quot;Giovanni Paolo II&quot;</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicola Silvestris, MD</last_name>
      <phone>+390805555419</phone>
      <email>n.silvestris@oncologico.bari.it</email>
    </contact>
    <contact_backup>
      <last_name>Michele Simone, MD</last_name>
      <phone>+390805555913</phone>
    </contact_backup>
    <investigator>
      <last_name>Oronzo Brunetti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonella Argentiero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia ASST pg23</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barbara Merelli, MD</last_name>
      <email>bmerelli@asst-pg23.it</email>
    </contact>
    <contact_backup>
      <last_name>Michele Colledan, MD</last_name>
      <email>mcolledan@asst-pg23.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica Azienda Universitaria Ospedaliera Policlinico Sant'Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mariacristina Di Marco, MD</last_name>
      <phone>+390512143836</phone>
      <email>mariacristina.dimarco@unibo.it</email>
    </contact>
    <contact_backup>
      <last_name>Riccardo Casadei, MD</last_name>
      <phone>+390512144728</phone>
      <email>riccardo.casadei@aosp.bo.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica dell'Az.Ospedaliera Fondazione Poliambulanza Istituto Ospedaliero</name>
      <address>
        <city>Brescia</city>
        <zip>25124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto Zaniboni, MD</last_name>
      <phone>+390303515309</phone>
      <email>alberto.zaniboni@poliambulanza.it</email>
    </contact>
    <contact_backup>
      <last_name>Moh'd Abu Hilal, MD</last_name>
      <phone>+390303518503</phone>
      <email>oncotrials@poliambulanza.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica AOU Careggi</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisa Giommoni, MD</last_name>
      <phone>+390557947298</phone>
      <email>elisa.giommoni@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Lorenzo Antonuzzo, MD</last_name>
      <email>antonuzzol@aou-careggi.toscana.it</email>
    </contact_backup>
    <investigator>
      <last_name>Coratti Andrea, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Ospedale Generale Provinciale</name>
      <address>
        <city>Macerata</city>
        <zip>62100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luca Faloppi, MD</last_name>
      <phone>+3907332572274</phone>
      <email>luca.faloppi@sanita.marche.it</email>
    </contact>
    <contact_backup>
      <last_name>Walter Siquini, MD</last_name>
      <phone>+3907332572400;</phone>
      <email>walter.siquini@sanita.marche.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica dell'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luca Frassineti, MD</last_name>
      <phone>+390543739100</phone>
      <email>luca.frassineti@irst.emr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncologia dell'Istituto Clinico Humanitas</name>
      <address>
        <city>Milan</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvia Bozzarelli, MD</last_name>
      <phone>+390282247255</phone>
      <email>silvia.bozzarelli@humanitas.it</email>
    </contact>
    <contact_backup>
      <last_name>Alessandro Zerbi, MD</last_name>
      <phone>+390282245941</phone>
      <email>alessandro.zerbi@hunimed.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Reni, MD</last_name>
      <phone>+390226437644</phone>
      <email>reni.michele@hsr.it</email>
    </contact>
    <contact_backup>
      <last_name>Maria Maddalena Valente, PhD</last_name>
      <phone>+390226437623</phone>
      <email>valente.mariamaddalena@hsr.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica Falck Niguarda</name>
      <address>
        <city>Milan</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katia Bencardino, MD</last_name>
      <phone>+390264442290</phone>
      <email>katia.bencardino@ospedaleniguarda.it</email>
    </contact>
    <contact_backup>
      <last_name>Giovanni Ferrari, MD</last_name>
      <phone>+390264447884</phone>
      <email>giovanni.ferrari@ospedaleniguarda.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica Az Ospedaliera AOU Cagliari Policlinico Universitario Dullio Casula</name>
      <address>
        <city>Monserrato</city>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario Scartozzi, MD</last_name>
      <phone>+39070051093217</phone>
      <email>marioscartozzi@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Adolfo Pisanu, MD</last_name>
      <phone>+390706095876</phone>
    </contact_backup>
    <investigator>
      <last_name>Roberto Ottonello, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica AOU FEDERICO II</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Bianco, MD</last_name>
      <phone>+390817462061</phone>
      <email>robianco@unina.it</email>
    </contact>
    <contact_backup>
      <last_name>Roberto Ivan Troisi, MD</last_name>
      <phone>+390817462710</phone>
    </contact_backup>
    <investigator>
      <last_name>Roberto Montalti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica 1 Ospedaliera Istituto Oncologico Veneto IRCCS</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sara Lonardi, MD</last_name>
      <phone>+390498215910</phone>
      <email>sara.lonardi@iov.veneto.it</email>
    </contact>
    <contact_backup>
      <last_name>Francesca Bergamo, MD</last_name>
      <email>francesca.bergamo@iov.veneto.it</email>
    </contact_backup>
    <investigator>
      <last_name>Letizzia Procacci, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica Arnas Civico</name>
      <address>
        <city>Palermo</city>
        <zip>90121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Livio Blasi, MD</last_name>
      <email>livio.blasi61@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Valentina Palmisano, MD</last_name>
      <email>valentina.palmisano@arnascivico.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica 2 Az. Ospedaliera Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enrico Vasile, MD</last_name>
      <phone>+3905992455</phone>
      <email>envasile@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ugo Boggi, MD</last_name>
      <phone>+3905996873</phone>
      <email>ugo.boggi@unipi.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica Az. Ospedaliera Fondazione Policlinico Universitario A. Gemelli IRCCS</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giampaolo Tortora, MD</last_name>
      <phone>+390630155202</phone>
      <email>giampaolo.tortora@policlinicogemelli.it</email>
    </contact>
    <contact_backup>
      <last_name>Sergio Alfieri, MD</last_name>
      <email>sergio.alfieri@policlinicogemelli.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Chirurgia Generale e Oncologica dell'AZ. Ospedaliera Ordine Mauriziano</name>
      <address>
        <city>Torino</city>
        <zip>10028</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Ferrero, MD</last_name>
      <phone>+390115082590</phone>
      <email>aferrero@mauriziano.it</email>
    </contact>
    <contact_backup>
      <last_name>Massimo Di Maio, MD</last_name>
      <phone>+390115085485</phone>
      <email>massimo@dimaio@unito.it</email>
    </contact_backup>
    <investigator>
      <last_name>Elisa Sperti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Donatella Marino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione Chirurgica Az. Ospedaliera AULSS2</name>
      <address>
        <city>Treviso</city>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Massani, MD</last_name>
      <phone>+390422322882</phone>
      <email>marco.massani@aulss2.veneto.it</email>
    </contact>
    <contact_backup>
      <last_name>Adolfo Favaretto, MD</last_name>
      <email>adolfo.favaretto@aulss2.veneto.it</email>
    </contact_backup>
    <investigator>
      <last_name>Cristina Nistri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SOC di Oncologia Az. Ospedaliera Sanitaria Universitaria Friuli Centrale-P.O. &quot;S. Maria della Misericordia&quot;</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Donatella Iacono, MD</last_name>
      <phone>+390432559330</phone>
      <email>donatella.iacono@asufc.sanita.fvg.it</email>
    </contact>
    <contact_backup>
      <last_name>Gianpiero Fasola, MD</last_name>
      <phone>+390432559330</phone>
      <email>gianpiero.fasola@asufc.sanita.fvg.it</email>
    </contact_backup>
    <investigator>
      <last_name>Alessandro Uzzau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergio Intini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chirurgia generale e del Pancreas Azienda Ospedaliera Universitaria Integrata</name>
      <address>
        <city>Verona</city>
        <zip>37136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudio Bassi, MD</last_name>
      <phone>+390458124533</phone>
      <email>claudio.bassi@aovr.veneto.it</email>
    </contact>
    <contact_backup>
      <last_name>Michele Milella, MD</last_name>
      <phone>+390458128519</phone>
      <email>michele.milella@aovr.veneto.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oncologia ULSS8 Berica</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Aprile, MD</last_name>
      <phone>+390444753259</phone>
      <email>giuseppe.aprile@aulss8veneto.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Reni M, Cereda S, Mazza E, Passoni P, Nicoletti R, Balzano G, Zerbi A, Arcidiacono PG, Staudacher C, Di Carlo V. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy. Am J Clin Oncol. 2008 Apr;31(2):145-50. doi: 10.1097/COC.0b013e31814688f7.</citation>
    <PMID>18391598</PMID>
  </reference>
  <reference>
    <citation>Reni M, Balzano G, Aprile G, Cereda S, Passoni P, Zerbi A, Tronconi MC, Milandri C, Saletti P, Rognone A, Fugazza C, Magli A, Di Muzio N, Di Carlo V, Villa E. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial. Ann Surg Oncol. 2012 Jul;19(7):2256-63. doi: 10.1245/s10434-011-2205-2. Epub 2012 Jan 12.</citation>
    <PMID>22237835</PMID>
  </reference>
  <reference>
    <citation>Reni M, Balzano G, Zanon S, Passoni P, Nicoletti R, Arcidiacono PG, Pepe G, Doglioni C, Fugazza C, Ceraulo D, Falconi M, Gianni L. Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma. Br J Cancer. 2016 Jul 26;115(3):290-6. doi: 10.1038/bjc.2016.209. Epub 2016 Jul 12.</citation>
    <PMID>27404453</PMID>
  </reference>
  <reference>
    <citation>Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R, Pinelli D, Mosconi S, Doglioni C, Chiaravalli M, Pircher C, Arcidiacono PG, Torri V, Maggiora P, Ceraulo D, Falconi M, Gianni L. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):413-423. doi: 10.1016/S2468-1253(18)30081-5. Epub 2018 Apr 4.</citation>
    <PMID>29625841</PMID>
  </reference>
  <reference>
    <citation>Reni M, Zanon S, Balzano G, Passoni P, Pircher C, Chiaravalli M, Fugazza C, Ceraulo D, Nicoletti R, Arcidiacono PG, Macchini M, Peretti U, Castoldi R, Doglioni C, Falconi M, Partelli S, Gianni L. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. Eur J Cancer. 2018 Oct;102:95-102. doi: 10.1016/j.ejca.2018.07.007. Epub 2018 Aug 24.</citation>
    <PMID>30149366</PMID>
  </reference>
  <reference>
    <citation>Reni M, Zanon S, Peretti U, Chiaravalli M, Barone D, Pircher C, Balzano G, Macchini M, Romi S, Gritti E, Mazza E, Nicoletti R, Doglioni C, Falconi M, Gianni L. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. Lancet Gastroenterol Hepatol. 2018 Oct;3(10):691-697. doi: 10.1016/S2468-1253(18)30196-1. Epub 2018 Jul 7.</citation>
    <PMID>30220407</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 28, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>PAXG</keyword>
  <keyword>mFOLFIRINOX</keyword>
  <keyword>resectable</keyword>
  <keyword>borderline resectable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

